Best response achieved in each patient and overall rates of hematologic or cytogenetic response after dasatinib treatment of patients with different BCR-ABL mutations. Individual mutations occurring in ≥ 5 patients are listed with dasatinib IC₅₀ values (in nanomolar), as reported by O'Hare et al³  and Redaelli et al.¹⁹  Other indicates total of all patients with other mutations that are not listed.